ClinicalTrials.gg
RecruitingNCT06328062Updated Aug 7, 2026

Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA

An interventional study of Mirogabalin and Pregabalin in Pain Postoperative, Osteoarthritis and Total Knee Arthroplasty, sponsored by Thammasat University Hospital. Recruiting at 1 site in Thailand. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Thammasat University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Pain, Postoperative with a site in Thailand — 5 open to participants now, 9 under way, 1 of them phase 3. Pain, Postoperative · Thailand.

Planned enrollment
31st of 63
80 · median 80
Started
2024
with 4 others
No phase
32 of 69
3 open now
Registered
62nd of 69
by date
Lead sponsor
3 of 69
Thammasat University Hospital

Among the 69 studies in Pain, Postoperative with a site in Thailand, this one is the 31st largest by planned enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2024, is one of 32 with no phase, and was the 62nd registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 69 studies in Pain, Postoperative with a site in Thailand are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Pain, Postoperative with a site in Thailand, or all of them as a file.
02

Study summary

The goal of this RCT is to compare efficacy between mirogabalin and pregabalin in pain reducing after unilateral primary total knee arthroplasty.

The main question[s] it aims to answer are:

  • Does mirogabalin have better pain reduction than pregabalin after unilateral primary total knee arthroplasty.

Participants will randomized to mirogabalin or pregabalin group and will take the drug for 2 weeks after TKA. Researchers will compare to pregabalin group to see pain and functional outcomes after TKA.

Read the detailed description

After surgery is complete, you will be randomly assigned to receive painkillers Mirogabalin or Pregabalin along with other standard medications.

Surgery by Mirogabalin group: Participants received 5 mg of mirogabalin, one tablet taken twice a day, after breakfast and dinner, for 2 weeks.

In the pregabalin group: Participants received 75 mg of pregabalin, one tablet taken daily before bedtime, for 2 weeks.

03

Conditions studied

  • Pain Postoperative
  • Osteoarthritis
  • Total Knee Arthroplasty

Keywords

  • mirogabalin
  • pregabalin
  • pain postoperative
  • TKA
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 50-85 years old
  2. Unilateral primary osteoarthritis undergoing primary TKA

Exclusion criteria

Exclusion Criteria:

  1. \<60
  2. Allergy to drug in this study
  3. Cannot underwent spinal anesthesia and adductor canal block
  4. Taking gabapentinoid within 3 months before surgery
  5. History of previous knee surgery
  6. Severe liver disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Mirogabalin

    Participants will receive 5 mg of mirogabalin, twice a day, after breakfast and dinner, for 2 weeks.

    Drug: Mirogabalin

  • Active comparator
    Pregabalin

    Participants will receive 75 mg of pregabalin, once a day before bedtime, for 2 weeks.

    Drug: Pregabalin

Interventions

  • Participants will receive 5 mg of mirogabalin, twice a day, after breakfast and dinner, for 2 weeks.

  • Participants will receive 75 mg of pregabalin, once a day before bedtime, for 2 weeks.

06

What researchers measure

Primary outcomes

  1. Pain score

    Visual analog scale at rest and motion (0-100 points, 0 mean best, 100 mean worst)

    Time frame: Every 6 hours after surgery for 2 days, then twice a day for 2 weeks, then once a week until 12 week after surgery.

Secondary outcomes

  1. Morphine consumption

    Total morphine consumption in hospital (mg)

    Time frame: 72 hours after surgery

  2. Range of motion

    Using long arm goniometer (degrees)

    Time frame: 24 hour, 48 hour, 2 week, 6 week and 12 week after surgery

  3. Knee society score

    report in point (0-100, 0 mean worst, 100 mean best)

    Time frame: 2 week, 6 week and 12 week after surgery

  4. Knee injury and Osteoarthritis Outcome Score (KOOS)

    report in point (0-100, 0 mean worst, 100 mean best)

    Time frame: 2 week, 6 week and 12 week after surgery

  5. Sedation score

    report in point (0-100, 0 mean best, 100 mean worst)

    Time frame: 24 hour, 48 hour, 2 week, 6 week and 12 week after surgery

  6. Incidence of Somnolence and dizziness

    Using scale "Mild, moderate and severe"

    Time frame: everyday until 14 days then once a week until 12 weeks after surgery

  7. Total hospital stay

    Number of days the patient stays for surgery

    Time frame: up to 1 week

07

Study locations

1 of 1 sites recruiting
  • Thammasat University Hospital
    Khlong Luang, Changwat Pathum Thani 12120, Thailand
    Recruiting
    • Yot Tanariyakul, M.D. · Contacty.tanariyakul@gmail.com · 6683930257
    • Yot Tanariyakul, M.D. · Principal investigator
    • Krit Boontanapibul, M.D. · Principal investigator
08

References and documents

Publications

  • Hannon CP, Fillingham YA, Browne JA, Schemitsch EH, Mullen K, Casambre F, Visvabharathy V, Hamilton WG, Della Valle CJ. The Efficacy and Safety of Gabapentinoids in Total Joint Arthroplasty: Systematic Review and Direct Meta-Analysis. J Arthroplasty. 2020 Oct;35(10):2730-2738.e6. doi: 10.1016/j.arth.2020.05.033. Epub 2020 May 26. PubMed 32586656 ↗
  • Kim JY, Abdi S, Huh B, Kim KH. Mirogabalin: could it be the next generation gabapentin or pregabalin? Korean J Pain. 2021 Jan 1;34(1):4-18. doi: 10.3344/kjp.2021.34.1.4. PubMed 33380563 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Aug 2026, 28 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 28 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2024
First posted
Mar 25, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Aug 31, 2026
CompletionEst.
Aug 31, 2026
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06328062
Lead sponsor
Thammasat University Hospital
Responsible party
Yot Tanariyakul (Principle investigator, Thammasat University Hospital) — Principal investigator
First posted
Mar 25, 2024
Start date
Apr 1, 2024
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Aug 7, 2026

Study contacts

Yot Tanariyakul, M.D.
Contact
y.tanariyakul@gmail.com
+66863930257

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirogabalin

Start the discussion